The global generative AI in life sciences market size is calculated at USD 233.74 million in 2024, grew to USD 282.31 million in 2025, and is predicted to hit around USD 1,544.13 million by 2034, expanding at a CAGR of 20.78% between 2024 and 2034. The North America generative AI in life sciences market size accounted for USD 95.83 million in 2024 and is anticipated to grow at the fastest CAGR of 20.93% during the forecast year.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Generative AI in Life Sciences Market
5.1. COVID-19 Landscape: Generative AI in Life Sciences Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Generative AI in Life Sciences Market, By Technology
8.1. Generative AI in Life Sciences Market, by Technology, 2024-2034
8.1.1. Novel molecule generation
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Protein sequence design
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Synthetic gene design
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Single-cell RNA sequencing
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Data augmentation for model training
8.1.5.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Generative AI in Life Sciences Market, By Application
9.1. Generative AI in Life Sciences Market, by Application, 2024-2034
9.1.1. Drug Discovery
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Biotechnology
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Medical Diagnosis
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Clinical Trials
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Precision and Personalized Medicine
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Patient Monitoring
9.1.6.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Generative AI in Life Sciences Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Technology (2021-2034)
10.1.2. Market Revenue and Forecast, by Application (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Technology (2021-2034)
10.1.3.2. Market Revenue and Forecast, by Application (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Technology (2021-2034)
10.1.4.2. Market Revenue and Forecast, by Application (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Technology (2021-2034)
10.2.2. Market Revenue and Forecast, by Application (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Technology (2021-2034)
10.2.3.2. Market Revenue and Forecast, by Application (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Technology (2021-2034)
10.2.4.2. Market Revenue and Forecast, by Application (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Technology (2021-2034)
10.2.5.2. Market Revenue and Forecast, by Application (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Technology (2021-2034)
10.2.6.2. Market Revenue and Forecast, by Application (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Technology (2021-2034)
10.3.2. Market Revenue and Forecast, by Application (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Technology (2021-2034)
10.3.3.2. Market Revenue and Forecast, by Application (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Technology (2021-2034)
10.3.4.2. Market Revenue and Forecast, by Application (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Technology (2021-2034)
10.3.5.2. Market Revenue and Forecast, by Application (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Technology (2021-2034)
10.3.6.2. Market Revenue and Forecast, by Application (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Technology (2021-2034)
10.4.2. Market Revenue and Forecast, by Application (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Technology (2021-2034)
10.4.3.2. Market Revenue and Forecast, by Application (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Technology (2021-2034)
10.4.4.2. Market Revenue and Forecast, by Application (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Technology (2021-2034)
10.4.5.2. Market Revenue and Forecast, by Application (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Technology (2021-2034)
10.4.6.2. Market Revenue and Forecast, by Application (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Technology (2021-2034)
10.5.2. Market Revenue and Forecast, by Application (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Technology (2021-2034)
10.5.3.2. Market Revenue and Forecast, by Application (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Technology (2021-2034)
10.5.4.2. Market Revenue and Forecast, by Application (2021-2034)
Chapter 11. Company Profiles
11.1. IBM Corporation
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. AiCure LLC
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. MosaicML
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. NVIDIA
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Insilico Medicine Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Writer
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. HealthArk
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample